Home
Conference Highlights
View All Conference Highlights
Year in Review / Wrap-Ups
Wrap-Ups
Year in Review
Contact Us
Year in Review / Wrap-Ups
Wrap-Ups
Wrap Ups
2023
2022
2021
2020
2019
2018
2016
ONS 2023 - Multiple Myeloma: Wrap-Up
ASCO 2022 – Wrap-Up
ASCO 2021 – Breast Cancer: Wrap-Up
ASH 2021 – Systemic Mastocytosis: Wrap-Up
ASH 2021 – Myelofibrosis: Wrap-up
SABCS 2021 – Wrap-Up
ASCO 2020 – Wrap Up
ASH 2020 – CLL: Wrap-Up
SABCS 2020 – Wrap-Up
ASH 2019 – Multiple Myeloma: Wrap-Up
ASH 2019 – Post Wrap-Up
ASH 2019 – Wrap-up
ESMO 2018 – Wrap-up
ASH 2016 – Wrap-up
Wrap-Up
Emerging Treatment Landscape for Multiple Myeloma
ONS 2023 - Multiple Myeloma: Wrap-Up
New targets and innovative therapies for multiple myeloma were highlighted in two sessions presented at ONS 2023.
Read More ›
Wrap-Up
Nursing Considerations for Select Multiple Myeloma Treatments
ONS 2023 - Multiple Myeloma: Wrap-Up
Specific factors to be considered are outlined for the management of multiple myeloma treated with certain therapies.
Read More ›
Wrap-Up
Adverse Event Management in Multiple Myeloma
ONS 2023 - Multiple Myeloma: Wrap-Up
Common treatment-related adverse events and management approaches to multiple myeloma were outlined in three separate sessions at the ONS 2023 Congress.
Read More ›
Wrap-Up
Shared Decision-Making and Self-Management of Cancer Through Patient Empowerment and Education
ONS 2023 - Multiple Myeloma: Wrap-Up
Approaches to help build healthcare professional and patient relationships and considerations for symptom management by patients with multiple myeloma are discussed.
Read More ›
Wrap-Up
Health Disparities in Marginalized Patient Populations with Cancer
ONS 2023 - Multiple Myeloma: Wrap-Up
Healthcare disparities among Black and LGBTQ+ and gender minorities negatively impact clinical outcomes and survivorship.
Read More ›
Wrap-Up
DESTINY-Breast04 Compared T-DXd with TPC in Patients with HER2-Low Breast Cancer
ASCO 2022 – Wrap-Up
DESTINY-Breast04 is the first trial comparing outcomes with trastuzumab deruxtecan (T-DXd) versus treatment of physician’s choice (TPC) in patients with HER2-low metastatic breast cancer treated with 1 or 2 prior lines of chemotherapy.
Read More ›
Wrap-Up
TROPiCS-02 Primary Results: Sacituzumab Govitecan versus Treatment of Physician’s Choice in Patients with Advanced Breast Cancer
ASCO 2022 – Wrap-Up
The TROPiCS-02 study aims to confirm optimal treatment choice in patients with hormone receptor–positive/HER2-negative metastatic breast cancer whose disease progresses after having received endocrine therapy (ET) plus cyclin-dependent kinase (CDK)4/6 inhibitor.
Read More ›
Wrap-Up
Ribociclib Efficacious in Patients with Unresectable or HR-Positive/HER2-Negative Metastatic Breast Cancer Receiving Fulvestrant or Exemestane After Not Responding to Prior Treatments
ASCO 2022 – Wrap-Up
Patients with hormone receptor (HR)-positive/HER2-negative metastatic breast cancer who had previously advanced on any cyclin-dependent kinase (CDK)4/6 inhibitor plus any endocrine therapy (ET) showed a substantial progression-free survival (PFS) advantage in the ribociclib-treated cohort.
Read More ›
Wrap-Up
Event-Free Survival by Residual Cancer Burden After Neoadjuvant Chemotherapy + Pembrolizumab for Early TNBC: KEYNOTE-522 Data
ASCO 2022 – Wrap-Up
Pembrolizumab plus chemotherapy increased event-free survival compared with chemotherapy alone, highlighting the relevance of neoadjuvant pembrolizumab therapy for improving survival in patients with early triple-negative breast cancer.
Read More ›
Wrap-Up
Revised Overall Survival and Progression-Free Survival Data from the FAKTION Study: Capivasertib + Fulvestrant in Metastatic, ER-Positive Breast Cancer
ASCO 2022 – Wrap-Up
Capivasertib plus fulvestrant’s PFS advantage benefitted a broader patient population, and overall survival (OS) data with improved biomarker analyses can now be reported.
Read More ›
Page 1 of 3
1
2
3
Home
Conference Highlights
View All Conference Highlights
Year in Review / Wrap-Ups
Wrap-Ups
Year in Review
Contact Us